Saurabh Saha - 21 Jul 2025 Form 4 Insider Report for Centessa Pharmaceuticals plc (CNTA)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: CNTA
Reported as of: 21 Jul 2025
Net transaction value: -$663,850
SEC form: 4
Accepted by SEC: 21 Jul 2025, 19:39:29 UTC
Prior SEC filing: 20 Jun 2025
Next SEC filing: 15 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Richard Menziuso, attorney-in-fact

Key filing fact

Saurabh Saha filed Form 4 for Centessa Pharmaceuticals plc (CNTA) on 21 Jul 2025.

Key facts

This page summarizes Saurabh Saha's Form 4 filing for Centessa Pharmaceuticals plc (CNTA).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 21 Jul 2025, 19:39.

Change

Previous filing in this sequence was filed on 20 Jun 2025.
Current net transaction value: -$663,850.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001861926 Primary reporting owner

SAHA SAURABH

Relationship: Chief Executive Officer, Director
Address: C/O CENTESSA PHARMACEUTICALS PLC, 3RD FL., 1 ASHLEY RD, ALTRINCHAM, CHESHIRE, UNITED KINGDOM
Signature: /s/ Richard Menziuso, attorney-in-fact
Signature date: 21 Jul 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CNTA transaction

Ordinary Shares

Options Exercise

Transaction value: $211,750
Shares: +55,000
Change %: +25%
Price: $3.85
Shares after: 276,017
Date: 21 Jul 2025
Ownership: Direct
Footnotes: F1

CNTA transaction

Ordinary Shares

Sale

Transaction value: $875,600
Shares: -55,000
Change %: -20%
Price: $15.92
Shares after: 221,017
Date: 21 Jul 2025
Ownership: Direct
Footnotes: F1, F2, F3

CNTA holding

Ordinary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 38,000
Date: 21 Jul 2025
Ownership: By trust
Footnotes: F1, F4

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CNTA transaction Derivative

Share Option (right to buy)

Options Exercise

Transaction value: $0
Shares: -55,000
Change %: -27%
Price: $0.000000
Shares after: 150,000
Date: 21 Jul 2025
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 55,000
Exercise price: $3.85
Footnotes: F1, F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 5 footnotes

Footnote F1

The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Footnote F2

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2024.

Footnote F3

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.80 to $16.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Footnote F4

These shares are held directly in a trust, for which the Reporting Person and his spouse serve as trustees.

Footnote F5

1/48th of the shares subject to such option shall vest and become exercisable in equal monthly installments with the first installment vesting on March 1, 2023.